Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes

Sodium–glucose co-transporter 2 (SGLT2) inhibitors are a new family of antidiabetic drugs that reduce blood glucose independent of insulin. In this review, we present the advantages and adverse effects of SGLT2 inhibitors plus insulin therapy as a treatment regimen for patients with type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yinqiu, Zhao, Chenhe, Ye, Yangli, Yu, Mingxiang, Qu, Xinhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174744/
https://www.ncbi.nlm.nih.gov/pubmed/32351447
http://dx.doi.org/10.3389/fendo.2020.00190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174744/
https://www.ncbi.nlm.nih.gov/pubmed/32351447
http://dx.doi.org/10.3389/fendo.2020.00190

Ejemplares similares